Assess whether biosimilarity is analytically justified (3e2c32)

Situation

Biosimilarity is analytically justified sits with 505(b)(2) development lead because a boxed-warning proposal from the review division hit a safety team sitting on a new disproportionate signal. Evidence is 505(b)(2) literature-to-product bridge table; write the Pharma & Life Sciences Pharmacovigilance option that extract can carry.

Decision

505(b)(2) development lead in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using 505(b)(2) literature-to-product bridge table after a boxed-warning proposal from the review division.

Hypotheses to test

• Authorize Proceed under protocol now; 505(b)(2) literature-to-product bridge table already has the discriminator after a boxed-warning proposal from the review division.
• Keep Pause the pathway in force until 505(b)(2) literature-to-product bridge table is completed after a boxed-warning proposal from the review division for 505(b)(2) development lead.
• Treat 505(b)(2) literature-to-product bridge table as Escalate safety review because both readings appear after a boxed-warning proposal from the review division.
• Refuse a Pharma & Life Sciences close: 505(b)(2) development lead does not have the page biosimilarity is analytically justified turns on in 505(b)(2) literature-to-product bridge table.

Analysis required

• Check whether 505(b)(2) literature-to-product bridge table supports the labeled claim 505(b)(2) development lead would keep.
• Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal.
• Trace CMC, labeling, or pharmacovigilance facts in 505(b)(2) literature-to-product bridge table after a boxed-warning proposal from the review division.
• For this Pharma & Life Sciences Pharmacovigilance file, read 505(b)(2) literature-to-product bridge table against a boxed-warning proposal from the review division and write the one fact that would move biosimilarity is analytically justified for 505(b)(2) development lead.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (505(b)(2) literature-to-product bridge table after a boxed-warning proposal from the review division). The follow-on Pharmacovigilance action is what 505(b)(2) development lead does next: implement the option, assign an owner, and log the missing fact.